Skip to main content
Equibles

UBS Group AG

Position in VCEL — Vericel Corp

CIK 1610520 ZURICH, V8
Back to VCEL Full portfolio

Position in VCEL

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$15,683,924
+$7,680,319 QoQ
Shares Held
352,527
+41.7% QoQ
Ownership
0.688%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#37
of 317 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 95% Shared 0% None 5%

Common Shares in VCEL Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

UBS Group AG holds $8,789,681,375 across 562 Biotechnology names. VCEL ranks #91 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 5,450,825 $1,020,369,609
2 ROIV
Roivant Sciences Ltd.
 17,466,641 $618,144,423
3 PTGX
Protagonist Therapeutics, Inc
 3,399,221 $416,676,508
4 VRTX
Vertex Pharmaceuticals Inc / Ma
 712,259 $353,800,411
5 MRNA
Moderna, Inc.
 4,463,211 $312,558,664
6 INSM
INSMED Inc
 2,584,446 $275,553,630
7 ABVX
Abivax S.A.
 1,844,918 $245,853,771
8 MDGL
Madrigal Pharmaceuticals, Inc.
 401,708 $215,697,109

All Filings in VCEL

Export CSV
26 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $15,683,924 352,527
2026-03-31 $8,003,605 248,791
2025-12-31 $6,032,034 167,510
2025-09-30 $5,836,959 185,477
2025-06-30 $9,525,411 223,864
2025-03-31 $8,816,063 197,581
2024-12-31 $6,463,948 117,719
2024-09-30 $2,896,785 68,563
2024-06-30 $2,859,562 62,327
2024-03-31 $6,503,383 125,017
2023-12-31 $3,396,553 95,382
2023-09-30 $1,337,279 39,895
2023-06-30 $1,452,455 38,660
2023-03-31 $872,884 29,771
2022-12-31 $2,203,788 83,667
2022-09-30 $65,168 2,809
2022-06-30 $85,586 3,399
2022-03-31 $1,461,646 38,243
2021-12-31 $4,539,307 115,504
2021-09-30 $2,967,235 60,804
2021-06-30 $2,085,562 39,725
2021-03-31 $555,999 10,009
2020-12-31 $28,354,417 918,213
2020-09-30 $197,566 10,662
2020-06-30 $108,873 7,878
2020-03-31 $13,525,089 1,474,928